Changes

==Cancer Category/Type==

==Cancer Category/Type==

Acute Myeloid Leukemia (AML);  

'''Acute Myeloid Leukemia (AML);'''

 

The most common chromosomal translocations is t(8;21)(q22;q22) in de novo AML (2) RUNX1-RUNX1T1. translocations confer a favorable prognosis in their respective diseases (2)  

The most common chromosomal translocations is t(8;21)(q22;q22) in de novo AML (2) RUNX1-RUNX1T1. translocations confer a favorable prognosis in their respective diseases (2)  

inv(16)(p13;q22) or t(16)(p13;q22), which disrupt CBFB the non-DNA-binding partner of RUNX1:  also translocation confer a favorable prognosis in their respective diseases (2)

inv(16)(p13;q22) or t(16)(p13;q22), which disrupt CBFB the non-DNA-binding partner of RUNX1 and the MYH11 gene:  also translocation confer a favorable prognosis in their respective diseases (2)

Mono- and biallelic mutations in RUNX1 include deletions, missense, splicing, frameshift, and nonsense mutations. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis (2)

Mono- and biallelic mutations in RUNX1 include deletions, missense, splicing, frameshift, and nonsense mutations. These mutations are mechanistically distinct from the chromosomal translocations and confer a worse prognosis (2)

T-cell Acute Lymphocytic Leukemia (B-ALL)

'''T-cell Acute Lymphocytic Leukemia (B-ALL)'''

 

B-cell Acute Lymphocytic Leukemia (B-ALL)  most common chromosomal translocations is t(12;21)(p13;q22) in acute lymphocytic leukemia (B-ALL) (2) ETV6-RUNX1. translocation confer a favorable prognosis in their respective diseases(2)

most common chromosomal translocations is t(12;21)(p13;q22) (ETV6-RUNX1) in B-cell acute lymphocytic leukemia (B-ALL) (2).  This translocation occurs in 25% of Pediatic B-ALL but only 2% of Adult B-ALL ( translocation confer a favorable prognosis in their respective diseases(2)

Chromic Myeloid Leukemia (CML)

'''Chromic Myeloid Leukemia (CML)'''

Myelodysplastic Syndrome (MDS)

'''Myelodysplastic Syndrome (MDS)'''

CCUS or ICUS

'''CCUS or ICUS'''

RUNX1 mutations are more common in clonal cytopenia of undetermined significance (CCUS) (2)

RUNX1 mutations are more common in clonal cytopenia of undetermined significance (CCUS) (2)

Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML)

'''Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML)'''

From Wang et al. 2017RUNX1 mutations are present in 5% to 18% of AML [59–62]. They are associated with ASXL1 [59], MLLPTD [62], and IDH1/IDH2 mutations [62] and are essentially mutually exclusive of NPM1 mutations [59, 62]. RUNX1 mutations were found to be associated with resistance to chemotherapy, inferior DFS, EFS [59, 61, 62], and OS [59–62]. More importantly, RUNX1 mutations were deemed to be an independent prognostic marker for shorter EFS in multivariable analysis [62]. An explorative subgroup analysis demonstrated that RUNX1-mutated AML patients benefited from allo-HSC in terms of RFS [62].

From Wang et al. 2017.  RUNX1 mutations are present in 5% to 18% of AML [59–62]. They are associated with ASXL1 [59], MLLPTD [62], and IDH1/IDH2 mutations [62] and are essentially mutually exclusive of NPM1 mutations [59, 62]. RUNX1 mutations were found to be associated with resistance to chemotherapy, inferior DFS, EFS [59, 61, 62], and OS [59–62]. More importantly, RUNX1 mutations were deemed to be an independent prognostic marker for shorter EFS in multivariable analysis [62]. An explorative subgroup analysis demonstrated that RUNX1-mutated AML patients benefited from allo-HSC in terms of RFS [62].

==Gene Overview==

==Gene Overview==